# Imunon, Inc. Common Stock (IMNN)

> Imunon, Inc. Common Stock (IMNN) trades at $0.5355 (-5.22%) as of 7:30:05 PM EST on Nov 20, 2026, -57.16% over the past month. Market cap is $3.47M, with 1.5 days to cover in short interest.

Canonical: https://massive.com/quote/imnn
Data as of: 2026-11-21T00:30:05.125Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.5355** -0.03 (-5.22%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$0.5446** +0.01 (+1.70%)
As of 7:30:05 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Imunon, Inc. Common Stock (IMNN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -5.22% |
| 1W | -14.86% |
| 1M | -57.16% |
| YTD | -85.94% |
| 1Y | -85.72% |
| 52-wk range | $0.50 – $4.35 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for IMNN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.53 – $0.58 |
| Open | $0.56 |
| Prev close | $0.57 |
| Volume | 49.7K |
| Market cap | $3.47M |
| Shares out | 6.49M |

## Valuation and profitability ratios

Valuation and profitability ratios for Imunon, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 1.34 |
| P/FCF | — |
| ROE | -574.1% |
| ROA | -125.4% |
| Debt/Equity | 2.38 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Imunon, Inc. Common Stock (IMNN) insider trading](https://massive.com/quote/imnn/insider-trading.md): open-market Form 4 buys and sells by Imunon, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Imunon, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Imunon, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2026.”
- Oct 27, 2026 · Investor presentation
  “On October 26, 2026, Imunon, Inc. (the "Company") made available an investor presentation (the "Investor Presentation"), which the Company expects to use in connection with investor calls and/or conferences.”
- Oct 21, 2026 · Divestiture agreement
  “On October 20, 2026, Imunon, Inc. entered into an Asset Purchase Agreement with VoxelDox Therapeutics, Inc., pursuant to which the Company agreed to sell to VoxelDox the Company's assets relating to ThermoDox®, including related trademarks, regulatory filings, clinical and preclinical data, manufacturing know-how and existing drug product vials.”
- Jun 30, 2026 · Cfo appointment
  “As a result of Mr. Church's retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company's new interim Chief Financial Officer under a master services agreement (the "Agreement"), dated June 24, 2026, between the Company and Danforth Health, Inc., a financial advisory services firm ("Danforth"). Mr. Blacher will serve as the Company's principal financial officer and principal accounting officer.”
- Jun 16, 2026 · Equity compensation grant
  “The amendment increased the aggregate number of shares of common stock that may be delivered pursuant to all awards granted under the Plan by an additional 1,000,000 shares so that the new aggregate share limit for the Plan is 1,265,004 shares.”

## Dividend history and stock splits

Imunon, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1.15-for-1 · Aug 7, 2025
- 1-for-15 · Jul 25, 2025
- 1-for-15 · Mar 1, 2022

## IMNN short interest

How heavily IMNN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.5 |
| Short interest | 215.65K |
| Avg volume | 144.67K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## IMNN news

The latest news and headlines about Imunon, Inc. Common Stock (IMNN).

- [IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.globenewswire.com/news-release/2026/11/12/3401495/0/en/imunon-reports-third-quarter-2026-financial-results-and-provides-business-update.html) · GlobeNewswire Inc. · Nov 12, 2026 · positive sentiment
- [IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer](https://www.globenewswire.com/news-release/2026/11/06/3397525/0/en/imunon-presents-new-translational-data-at-sitc-2026-demonstrating-how-imnn-001-activates-and-sustains-anti-tumor-t-cell-immunity-in-advanced-ovarian-cancer.html) · GlobeNewswire Inc. · Nov 6, 2026 · positive sentiment
- [IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026](https://www.globenewswire.com/news-release/2026/03/24/3261137/0/en/IMUNON-to-Hold-2025-Financial-Results-and-Business-Update-Conference-Call-on-Tuesday-March-31-2026.html) · GlobeNewswire Inc. · Mar 24, 2026 · neutral sentiment
- [IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call](https://www.globenewswire.com/news-release/2025/08/05/3127782/0/en/IMUNON-Recaps-Highlights-from-2025-Second-Quarter-Financial-Results-Conference-Call.html) · GlobeNewswire Inc. · Aug 5, 2025 · positive sentiment
- [IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules](https://www.globenewswire.com/news-release/2025/05/23/3087765/0/en/IMUNON-Announces-Up-To-9-75-Million-Private-Placement-Priced-At-The-Market-Under-Nasdaq-Rules.html) · GlobeNewswire Inc. · May 23, 2025 · positive sentiment

## About Imunon, Inc. Common Stock

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Listed | Jul 24, 1995 |

[Company website](https://www.imunon.com)

## FAQ

### What is the Imunon, Inc. Common Stock (IMNN) stock price today?

Imunon, Inc. Common Stock (IMNN) is trading at $0.5355 (-5.22% on the day) as of 7:30:05 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Imunon, Inc. Common Stock?

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from…

### What is the short interest in IMNN?

As of Oct 30, 2026, IMNN has 215.65K shares short and 1.5 days to cover.

### What exchange is IMNN listed on?

Imunon, Inc. Common Stock (IMNN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time IMNN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=IMNN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Imunon, Inc. Common Stock (IMNN) insider trading](https://massive.com/quote/imnn/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
